Sydney, Australia 4 April 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to provide an update on copper-67 (Cu-67 or 67Cu) production by NorthStar Medical Radioisotopes, LLC (NorthStar). NorthStar, a global innovator in the…
Sydney, Australia 1 March 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of the world leading expert in copper-67 isotope (Cu-67 or 67Cu) production, Jon Stoner, to Clarity’s Scientific Advisory…
Sydney, Australia 16 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its Phase II diagnostic 64Cu SARTATE trial (DISCO NCT044383041) for patients with known or suspected neuroendocrine tumours (NETs) has reached the…
Sydney, Australia 14 February 2023 Highlights PROPELLER trial achieved all primary and secondary objectives 64Cu SAR-bisPSMA was safe and well tolerated by trial participants Uptake of Clarity’s 64Cu SAR-bisPSMA in cancer lesions is higher compared to the approved standard-of-care for prostate cancer imaging in Australia and the US, 68Ga PSMA-11 Greater uptake into cancer lesions…
Sydney, Australia 2 March 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, notes the recent supply interruption for Novartis’ Pluvicto™ radiotherapy to patients1-2 and confirms Clarity’s Targeted Copper Theranostics (TCTs) products and clinical development programs are…
Sydney, Australia 1 February 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that Cheryl Maley has joined Clarity’s Board of Directors as a Non-Executive Director. Dr Gillies O’Bryan-Tear has resigned from the…
Sydney, Australia 14 December 2022 Highlights Clarity’s diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER meets all primary and secondary objectives 64Cu SAR-bisPSMA is safe and well tolerated in trial participants 64Cu SAR-bisPSMA is shown to be efficacious in the detection of primary prostate cancer A dose of 200 megabecquerels (MBq) of 64Cu SAR-bisPSMA was determined…
Sydney, Australia 21 November 2022 Highlights Clarity’s fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR Bombesin are now under IND for US clinical…
Sydney, Australia 2 November 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the Phase II diagnostic 64Cu SAR-Bombesin trial (BOP) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 15…
Sydney, Australia 27 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer has reached the fifty percent recruitment milestone, with 25 out…